These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6334796)

  • 1. [Branhamella catarrhalis--a respiratory tract pathogen with the ability to produce beta-lactamases].
    Malmvall BE
    Lakartidningen; 1984 Oct; 81(43):3931-2. PubMed ID: 6334796
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug-resistance analysis of Gram-negative bacilli producing extended-spectrum beta-lactamases in lower respiratory tract infection].
    Long J; Lü SC
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):439-40, 444. PubMed ID: 15090319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Branhamella catarrhalis: an unappreciated pulmonary pathogen.
    Roth RM; Gleckman RA; Hibert DM
    Am Fam Physician; 1984 Oct; 30(4):169-73. PubMed ID: 6333806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of respiratory infection caused by Branhamella catarrhalis with special reference to beta-lactamase producing strains.
    Nagatake T
    Tohoku J Exp Med; 1985 Sep; 147(1):1-13. PubMed ID: 3000026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moraxella catarrhalis, a human respiratory tract pathogen.
    Murphy TF; Parameswaran GI
    Clin Infect Dis; 2009 Jul; 49(1):124-31. PubMed ID: 19480579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children].
    Köseoğlu O; Ergin A; Gürkan Aydin N; Hasçelik G
    Mikrobiyol Bul; 2004 Oct; 38(4):335-40. PubMed ID: 15700658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Branhamella catarrhalis and bronchopulmonary infection].
    Blanquer R; Chiner E; Blanquer J; Borrás R; Muñoz J; Cosín JA
    Rev Clin Esp; 1988 Sep; 183(4):167-9. PubMed ID: 3149788
    [No Abstract]   [Full Text] [Related]  

  • 8. [Respiratory tract infection with Branhamella catarrhalis].
    Matsumoto K; Nagatake T; Uzuka Y; Rikitomi N; Noguchi Y
    Nihon Naika Gakkai Zasshi; 1982 Dec; 71(12):1696-702. PubMed ID: 6984859
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
    Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of extended-spectrum beta-lactamases.
    BMJ Group
    Drug Ther Bull; 2008 Mar; 46(3):21-4. PubMed ID: 18337463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic-sensitivity of Moraxella catarrhalis isolated from clinical materials in 1997-1998.
    Mikucka A; Janicka G; Krawiecka D; Kochanowska J
    Med Sci Monit; 2000; 6(2):300-4. PubMed ID: 11208326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microbiol landscape and production of beta-lactamases with extended spectrum activity in patients with urinary tract infection].
    Zhevlakova IuA; Zakharova GV; Khokhlova OI; Ust'iantseva IM
    Klin Med (Mosk); 2009; 87(3):56-9. PubMed ID: 19469259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections.
    Varon E; Levy C; De La Rocque F; Boucherat M; Deforche D; Podglajen I; Navel M; Cohen R
    Clin Infect Dis; 2000 Aug; 31(2):477-81. PubMed ID: 10987708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of several antibiotics on pathogenic micro-organisms isolated from the lower respiratory tract].
    Allocco A; Tullio V; Cuffini AM; Carlone NA
    G Batteriol Virol Immunol; 1994; 86(1-12):15-28. PubMed ID: 8706972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histidine decarboxylases from bacteria that colonise the human respiratory tract.
    Cundell DR; Devalia JL; Wilks M; Tabaqchali S; Davies RJ
    J Med Microbiol; 1991 Dec; 35(6):363-6. PubMed ID: 1721655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Haemophilus spp. and Branhamella catarrhalis in upper respiratory tract infections.
    Russo G; Stefani S; Oliveri S
    J Chemother; 1991 Jan; 3 Suppl 1():15-8. PubMed ID: 12041752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Occurrence of extended spectrum beta-lactamases (ESBL) and inducible beta-lactamases (IBL) in clinical strains of gram-negative rods].
    Rokosz A; Sawicka-Grzelak A
    Med Dosw Mikrobiol; 1998; 50(1-2):31-9. PubMed ID: 9857611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.